Clinical Trials Logo

Ovarian Granulosa Cell Tumor clinical trials

View clinical trials related to Ovarian Granulosa Cell Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT05348356 Active, not recruiting - Ovarian Cancer Clinical Trials

Nirogacestat in Ovarian Granulosa Cell Tumors

Start date: August 30, 2022
Phase: Phase 2
Study type: Interventional

This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

NCT ID: NCT01042522 Active, not recruiting - Clinical trials for Ovarian Gynandroblastoma

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Start date: February 8, 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies paclitaxel and carboplatin to see how well they work compared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating patients with sex cord-ovarian stromal tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating sex cord-ovarian stromal tumors.

NCT ID: NCT00748657 Completed - Clinical trials for Malignant Ovarian Epithelial Tumor

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Start date: September 22, 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well bevacizumab works in treating patients with sex cord-stromal tumors of the ovary that have come back. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.